Quality of life in prostate cancer patients

Ca-A Cancer Journal for Clinicians

Volumn 47, Issue 4, 1997, Pages 207-217

  Herr, Harry W ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN DERIVATIVE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MALE SEXUAL DYSFUNCTION; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REGRESSION ANALYSIS; SURVIVAL TIME;

EID: 0030876421     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.47.4.207     Document Type: Article

References (40)

1. Testa MA, Simonson DC. Assessment of quality-of-life outcomes. N Engl J Med 1996;334:835-840.
2. Osoba D: Lessons learned from measuring health-related quality of life in oncology J Clin Oncol 1994;12:608-616.
3. Kornblith AB. Holland JC: Model for quality-of-life research from the Cancer and Leukemia Group B: The telephone interview. conceptual approach to measurement. and theroretical framework. J Natl Cancer Inst Monogr 1996;20:55-62.
4. Fowler FJ Jr. Barry MJ. Lu-Yao G. et al: Patient-reported complications. The National Medicare Experiance prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993) Urology 1993;42:622-629.
5. Jonler M. Messing EM. Rhodes PR. et al: Sequelae of radical prostatectomy. Br J Urol 1994:74:352-358.
6. Geary ES. Dendinger TE. Stamey TA: Impotence, incontinence and vesical neck strictures following nerve-sparing radical prostatectomy. J Urol 1994:151(Suppl):488A. Abstract.
7. Murphy GP. Mettlin C. Menck H. et al: National patterns of prostate cancer treatment by radical prostatectomy: Result of a survey by the American College of Surgeons Commission on Cancer. J Urol 1994;152:1817-1819.
8. Fowler FJ Jr. Barry MJ. Lu-Yao G. el al: Effect of radical prostatectomy for prostate cancer on patient quality of life: Result from a Medicare survey. Urology 1995;43:1007-1015.
9. Chodak GW. Sinner M. Rukstails DB. et al: Patient-reported outcomes following radical prostatectomy preformed at eight academic institutions. J Urol 1995;153:390. Abstract.
10. Skinner EC. Perez M. Lieskovsky G. et al: Quality of life following radical prostatectomy for carcinoma of the prostate. J Urol 1995;153:506.
11. Litwin MS, Hays RD, Fink A. et al: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129-135.
12. McCammon KA. Schellhammer PF: Comparison of quality of life after radiation therapy or radical prostatectomy for localized carcinoma of the prostste. J Urol 1996;155:647. Abstract.
13. Thrasher JB. Kao T-C. Garner D. et al: Multicenter patient self-reported questionnaire of incontinence. impotence and quality of life after radical prostatectomy. J Urol 1996:647. Abstract.
14. Talcott JA. Rieker P. Propert KJ. et al: Long-term complications of treatment for early prostate cancer. 2-year follow-up in a prospective multistudy. Proc Am Soc Clin Oncol 1996:15:252. Abstract.
15. Widmark A. Fransson P. Tavellin B: Self-assessment questionnaire for evaluating urinary and intestinal side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population. Cancer 1994;74:2520-2532.
16. Jonler M. Ritter MA. Brinkmann R. et al: Sequelae of definitive radiation therapy for prostate cancer localized to the pelvis Urology 1994;74:876-882.
17. Chinn DM. Holland J. Crownover RL. et al: Potency following high-dose three-dimensional conoformal radiotherapy and the impact of prior major urologic surgical procedures in patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 1995;33:15-22.
18. Zincke H. Oesterling JE. Blute ML. et al: Long-term (15 years) result after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.
19. Braslis KG. Santa-Cruz C. Brickman AL. et al: Quality of life 12 Months after radical prostatectomy. Br J Urol 1995;75:48-53.
20. Mazur DJ, Merz JF: Older patients' willingness to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of Prostate cancer. J Am Geriatr Soc 1995;43:979-984.
21. Chapman GB, Bennett CL, Elstein AS: Prostate cancer patients' utilities for health states: A pilot study. Proc Am Soc Clin Oncol 1996;15:509. Abstract.
22. Simpson KN, Revicki DA, Qaqish BF, et al: Quality of life with clinically localized prostatic car- cinoma: Prostatectomy versus watchful waiting. J Urol 1995;153:251. Abstract.
23. Cowen ME, Cahill D, Dattan MW, et al: The value or utility of prostate cancer states. J Urol 1996';155:376 Abstract.
24. Lu-Yao GL, Potosky AL, Albertson PC et al: Follow-up prostate cancer treatments after radical prostatectomy: A population-based study. J Natl Cancer Inst 1996;88:166-173.
25. Herr HW: Quality of life of incontinent men after radical prostatectomy. J Urol 1994;151:652-654.
26. McLachlan SA, Tannock IF: The EORTC OLQ-C30 and utilities by time trade-off (TTO) measure different aspects of health outcome in women with metastatic breast cancer. Proc Am Soc Clin Oncol 1996;15:509. Abstract.
27. Kornblith AB, Herr HW, Ofman US, et al: Quality of life of patients with prostate cancer and spouses: The value of a data base in clinical care. Cancer 1994;73:2791-2802.
28. Klein CE, Prochazka A, Spitzer AL, et al: Spousal report of life quality of life in treatment for localized prostate cancer. Proc Am Soc Clin Oncol 1996;15:508. Abstract.
29. Herr HW, Kornblith AB, Ofman U: A comparison of the quality of life of patients with metastatic Prostate cancer who received or did not receive hormonal therapy. Cancer 1993;71(Suppl 3):1143-1150.
30. Herr HW: Quality of life of prostate cancer patients on or off hormone therapy. Proc Am Soc Clin Oncol 1995;14:231. Abstract.
31. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trial with 3283 deaths in 5710 patient, Laucet 1995;346:265:269.
32. Klotz LH, Herr HW, Morse MJ, et al: Intermittent endocrine therapy for advanced prostate cancer. Cancer 1986;58:2546-2550.
33. Goldenberg SL, Bruchovsky N, Gleave ME, et al: Intermittent androgen suppression in the treatment of prostate cancer. J Urol 1995;153:448. Abstract.
34. Bales GT, Sinner MB, Kim JH, et al: Impact of intermittent androgen deprivation on quality of life. J Urol 1996;155:578. Abstract.
35. Fossa SD, Aaronson NK, Newling D, et al: Advanced hormone resistant prostatic cancer: Preliminary observations on subjective morbidity and palliation. Eur Urol 1990;18 (Suppl 1):2. Abstract.
36. Tannock I, Gospodarowciz M, Meakin W, et al: Treatment of metastatic prostatic cancer with low-dose prednisone Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989;7:590-597.
37. Tannock I, Osoba D, Ernst S, et al: Chemotherapy with mitoxantrone and prednisone palliates patients with hormone-resistant prostate cancer Proc Am Soc Clin Oncol 1995;142:45. Abstract.
38. Kantoff PW, Conaway M, Picus WE, et al: Hydrocortisone with or without mitoxantrone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1996;15:1748. Abstract.
39. Stockler M, Osaba D, Goodwin P, et al: Validation of the PROSQOLI: A pragmatic outcome measure for clinical trials in advanced prostate cancer. Proc Am Soc Clin Oncol 1995;14:244. Abstract.
40. Spiegel D: Psychosocial intervention is cancer. J Natl Cancer Inst 1993;85:1198-1205.